- 收听数
- 0
- 性别
- 保密
- 听众数
- 23
- 最后登录
- 2024-2-19
- QQ
 - UID
- 2826
- 阅读权限
- 40
- 帖子
- 2223
- 精华
- 0
- 在线时间
- 2729 小时
- 注册时间
- 2013-1-27
- 科研币
- 26
- 速递币
- 22350
- 娱乐币
- 2910
- 文献值
- 903
- 资源值
- 10
- 贡献值
- 0
|
速递书局
| 封面: |
 |
| 题名: |
Biosimilars and Interchangeable Biologics: Strategic Elements |
| 作者: |
Sarfaraz K. Niazi |
| 出版社: |
CRC |
| 出版日期: |
2015-12-01 |
| ISBN: |
9781498743488 |
| 附属页: |
齐全 |
| 书签: |
有 |
| 格式: |
清晰PDF |
| 内容简介: |
Features
Examines the regulatory, marketing, and intellectual property challenges to carve out a stable marketing strategy
Features an understanding of global regulations in developing a comprehensive plan
Incorporates the author’s firsthand experience in developing biosimilar drugs for both the US and European markets
Summary
What’s the Deal with Biosimilars?
Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development.
Part of a two-volume set that covers varying aspects of biosimilars, Biosimilars and Interchangeable Biologics: Strategic Elements explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets.
Of specific interest to practitioners, researchers, and scientists in the biopharmaceutical industry, this volume examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book also presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle. |
| 求助帖链接: |
http://www.expaper.cn/forum.php?mod=viewthread&tid=106107 |
本帖最后由 eli.123 于 2016-1-10 14:24 编辑
75 MB, PDF
|
本帖子中包含更多资源
您需要 登录 才可以下载或查看，没有帐号？快速注册
-
总评分: 速递币 + 50
文献值 + 4
查看全部评分
|
发表于 2016-1-10 14:05:19
淘帖
收藏
顶
踩
